Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Population-Scale Genome Survey Supports Interpretation of Genetic Testing

By LabMedica International staff writers
Posted on 25 Oct 2026

Whole-genome sequencing is increasingly used to diagnose genetic disease and assess inherited risk. More...

Interpreting its findings requires clinicians and patients to distinguish disease-linked variants from the broad genetic variation present in healthy populations. Population-scale context is therefore essential when considering genetic findings alongside symptoms, family history, and environmental factors. 

A University of Exeter-led study characterized the “average” human genome using whole-genome sequencing data from nearly 1 million individuals. The work examined normal human genetic variation and how it relates to genetic disease risk. The paper, titled “The average individual genome: a survey of nearly 1 million whole-genome sequences,” was published in Genome Medicine and presented at the American Society of Human Genetics (ASHG) annual meeting.

Drawing on two major population biobanks, UK Biobank and the U.S. All of Us study, the team found that each genome contained around 5 million variants, defined as DNA locations that differ between individuals. About 10,000 of these altered gene sequences, with potential effects ranging from lactose intolerance to drug response, although many were biologically neutral.

Within this variation, every person carried between one and three rare variants previously shown to cause serious genetic diseases, alongside about 50 rare variants of uncertain clinical relevance. The team also assessed polygenic risk scores for 28 common conditions, including diabetes, cardiovascular disease, and schizophrenia. These scores indicated that most people would be categorized as having high genetic risk for around three conditions.

The researchers did not examine participants’ health status, so many individuals with disease-linked findings may not have had the associated diseases. They concluded that such findings can reflect normal genetic variation and that other factors remain important in disease development. In a separate analysis of participants recruited with their parents, the team identified around 63 de novo variants per person, with the number increasing particularly with paternal age.

“Whole genome sequencing has become such an important tool in diagnosing genetic disease, and we're increasingly moving toward genetic screening for predicting disease. Yet most people are unaware of just how much genetic variation is present in every genome. Actually, variation is the norm. For the first time, our study outlines what to expect in the average human genome, which can benefit clinicians and patients across the world in understanding, interpreting and contextualizing genomics,” said Caroline Wright, senior author and professor at the University of Exeter.

“Importantly, we found that everyone carries a small number of genetic variants linked to disease, although many of these will not actually cause disease in that individual. It is therefore crucial to consider context when interpreting findings from genetic testing, including symptoms or family history of disease as well as other clinical and environmental risk factors. Our findings also provide important context for professionals who are interpreting genetic testing results or commissioning genetic screening programs,” said Prof. Wright.

Related Links
University of Exeter


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
Fully Automated Urinalysis System
DxU 1800 Fully Automated Urinalysis System
Gold Member
Nucleic Acid Extractor System
NEOS-96 XT
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Researchers combined a blood-based biomarker of Alzheimer’s disease with age, sex, and genetic risk to estimate future cognitive impairment risk in asymptomatic adults (Image Credit: Adobe Stock)

Blood Biomarker Model May Help Estimate Five- and 10-Year Cognitive Impairment Risk

Estimating future cognitive impairment risk remains challenging in cognitively healthy adults, particularly when biomarker findings are reduced to simple positive or negative results. Because mild cognitive... Read more

Molecular Diagnostics

view channel
Image Credit: Shutterstock

Lung Cancer Atlas Reveals Cellular Patterns Associated With Patient Prognosis

Lung cancer is a leading cause of cancer-related death worldwide and is characterized by substantial cellular heterogeneity. Even within a single tumor, cancer cells can vary in aggressiveness, while immune,... Read more

Immunology

view channel
Image: The panel expands Cepheid’s respiratory testing portfolio on the GeneXpert platform, offering laboratories greater flexibility in selecting tests based on clinical needs. (Photo courtesy of Cepheid)

Multiplex PCR Test Gains CE Marking to Support Respiratory Infection Diagnosis

Acute respiratory infections often present with overlapping symptoms, making it difficult to distinguish between viral and bacterial causes. Seasonal surges of influenza-like illness in Europe further... Read more

Microbiology

view channel
Image: Malaria is caused by Plasmodium parasites, primarily transmitted through the bites of infected female Anopheles mosquitoes (Image Credit: Adobe Stock)

Complete Malaria Genomes Could Improve Species Identification and Surveillance

Malaria remains a major global health challenge, with an estimated 282 million cases and 610,000 deaths worldwide in 2024. Although most research has focused on Plasmodium falciparum, Plasmodium ovale... Read more

Industry

view channel
Image: The TOMR trial uses Signatera-guided MRD testing to identify high-risk patients for curative-intent treatment.

Natera and Incyte Collaborate on MRD-Guided Colorectal Cancer Treatment Study

Natera (Austin, TX, USA) has entered into a clinical collaboration with Incyte (Wilmington, DE, USA) for a Phase II study evaluating molecular residual disease (MRD)-guided treatment in colorectal cancer.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.